title: Quantitative changes in endogenous DNA adducts correlate with conazole in vivo mutagenicity and tumorigenicity.
abstract: The mouse liver tumorigenic conazole fungicides triadimefon and propiconazole have previously been shown to be in vivo mouse liver mutagens in the Big Blue™ transgenic mutation assay when administered in feed at tumorigenic doses, whereas the nontumorigenic conazole myclobutanil was not mutagenic. DNA sequencing of the mutants recovered from each treatment group as well as from animals receiving control diet revealed that propiconazole- and triadimefon-induced mutations do not represent general clonal expansion of background mutations, and support the hypothesis that they arise from the accumulation of endogenous reactive metabolic intermediates within the liver in vivo. We therefore measured the spectra of endogenous DNA adducts in the livers of mice from these studies to determine if there were quantitative or qualitative differences between mice receiving tumorigenic or nontumorigenic conazoles compared to concurrent control animals. We resolved and quantitated 16 individual adduct spots by (32)P postlabelling and thin layer chromatography using three solvent systems. Qualitatively, we observed the same DNA adducts in control mice as in mice receiving conazoles. However, the 13 adducts with the highest chromatographic mobility were, as a group, present at significantly higher amounts in the livers of mice treated with propiconazole and triadimefon than in their concurrent controls, whereas this same group of DNA adducts in the myclobutanil-treated mice was not different from controls. This same group of endogenous adducts were significantly correlated with mutant frequency across all treatment groups (P = 0.002), as were total endogenous DNA adduct levels (P = 0.005). We hypothesise that this treatment-related increase in endogenous DNA adducts, together with concomitant increases in cell proliferation previously reported to be induced by conazoles, explain the observed increased in vivo mutation frequencies previously reported to be induced by treatment with propiconazole and triadimefon.
authors.affiliation: National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC 27711, USA. ross.jeffrey@epamail.epa.gov
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Ross
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Leavitt
authors.forename: Judith E
authors.initials: JE
authors.lastname: Schmid
authors.forename: Garret B
authors.initials: GB
authors.lastname: Nelson
mesh_terms: D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000235:genetics*; D018736:DNA Adducts / Q000187:drug effects*; D008099:Liver / Q000187:drug effects; D008297:Male; D051379:Mice; D009153:Mutagens / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity*; D009154:Mutation / Q000187:drug effects; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity*
chemical_list: D018736:DNA Adducts; D009153:Mutagens; D014230:Triazoles; C045950:propiconazole; C032910:triadimefon